Recovery and healing peptides

The counts come straight from PubMed and ClinicalTrials.gov and are the same figures our human trials by peptide register uses. Read them with one caution: they count every trial in which people were given the molecule, for any purpose. Most of those trials were not about recovery. One of ipamorelin's two was about bowel function after surgery and the other measured how the body handles the drug; sermorelin's and CJC-1295's are growth-hormone studies; GHK-Cu's one was a skin cream after laser treatment. For BPC-157, the peptide most often sold for tendons and muscle, the published count is zero.

Counted from PubMed and ClinicalTrials.gov on October 9, 2026.

Each name links to that peptide's own section of studies. Where each one stands in US law is kept in one place, the peptide regulatory status tracker, because it moves.

The phrase covers two unrelated products. The peptides on this page are prescription compounds, usually injected. Collagen peptides sold in the supplement aisle are protein fragments from food sources, taken by mouth, and regulated as dietary supplements under a different set of rules from drugs ^[12]. Research on one says nothing about the other, and a search for "recovery peptides" returns both.

BPC-157 is a synthetic 15-amino-acid sequence corresponding to a partial sequence of a larger "Body Protection Compound" originally identified in gastric juice. It was characterized and named by Predrag Sikiric's group at the University of Zagreb beginning in the 1990s. The literature on BPC-157 is unusual in two ways. First, it is voluminous — the 2025 Pharmaceuticals literature and patent review ^[1] and the 2019 Cell and Tissue Research review of musculoskeletal soft tissue applications ^[2] each cite dozens of preclinical papers. Second, the vast majority of that literature is preclinical — rat and mouse models of wound healing, tendon repair, GI ulcer protection, and angiogenesis.

The 2025 HSS Journal systematic review focused specifically on BPC-157 in orthopaedic sports medicine and synthesized the human evidence such as it is — predominantly case series and preclinical extrapolation ^[3]. A 2021 Frontiers in Pharmacology review covered the wound-healing literature in detail ^[4]. The 2025 Current Reviews in Musculoskeletal Medicine narrative review took the deliberately even-handed title "Regeneration or Risk?" and is the cleanest editorial-tone summary of the field ^[5].

The one human report most often cited is a 2021 paper in Alternative Therapies in Health and Medicine on intra-articular BPC-157 for knee pain ^[6]. We treat it as Tier B evidence: the journal is not high-impact, there was no control group, and the sample was small. It is the kind of report that motivates a controlled trial, and no such trial has been published. The registered ones are listed on the BPC-157 monograph, linked from the table.

On the law: BPC-157 left the FDA's Category 2 list in April 2026 when its nomination was withdrawn, and an FDA advisory committee voted in July 2026 to recommend it for the list of substances pharmacies may compound. Neither step makes it legal to buy ^[10]. Since October 28, 2026 HHS has said it will not act against licensed pharmacies that compound BPC-157, or TB-500, for a named patient under set conditions; research-chemical sellers are outside that policy ^[13]. The full answer is on the monograph: is BPC-157 legal?

TB-500 is a synthetic copy of seven amino acids from Thymosin Beta-4, a 43-amino-acid protein found in nearly all human tissues. The marketing framing — "TB-500 = TB-4" — is incorrect. Full-length Thymosin Beta-4 has been through clinical trials, as eye drops for dry eye and damaged cornea, as a gel for wounds and, in China, as an injection after heart attack, which is where the registered trials in the table come from. None of those tested the seven-amino-acid fragment sold for tendons and muscle.

The 2026 American Journal of Sports Medicine primer for orthopaedic and sports medicine physicians covers the broader injectable peptide landscape including TB-500 and is the cleanest single overview ^[7]. The 2026 JAAOS Global Research Reviews paper similarly surveys orthopaedic applications ^[8]. The 2026 Sports Medicine (Auckland) review on approved and unapproved peptide therapies is the most thorough critical assessment of the category ^[9].

Across these reviews, the consistent conclusion: animal-model data is suggestive, the proposed mechanism (anti-inflammatory, pro-angiogenic, actin-binding promoting cellular migration) is biologically plausible, and the human-trial evidence does not yet support routine clinical recommendation. TB-500 is best understood as a research compound that has migrated into commercial use ahead of the data. More on the TB-500 monograph, and the two compared on BPC-157 vs TB-500.

KPV is a three-amino-acid fragment sold for inflammation and gut healing. It has no published trial and no registered trial in people; everything claimed for it comes from cell and animal work. It left the FDA's Category 2 list in April 2026 alongside BPC-157 ^[10].

GHK-Cu is a copper-binding peptide with a long record in skin care. Its one published trial in people tested a cream on skin after laser resurfacing. Injected GHK-Cu, the form sold for healing from the inside, has no published human trial.

Ipamorelin, CJC-1295 and sermorelin do not act on tissue directly. They push the body to release more growth hormone, and the recovery claim rests on what growth hormone does, not on trials of these peptides in injured people. The trials they do have measured hormone levels or tested unrelated uses. Their monographs set out what each one has behind it and where it stands with the FDA.

WADA prohibits BPC-157 at all times and names it explicitly under S0, the category for substances with no current approval for human therapeutic use ^[11]. TB-500, ipamorelin, CJC-1295 and sermorelin are prohibited at all times under S2, peptide hormones, growth factors, related substances and mimetics ^[11]. KPV and GHK-Cu are not named in WADA's list search; WADA itself tells athletes who cannot find a substance to check with their anti-doping organization ^[11].

An athlete subject to testing — which includes NCAA student-athletes through the WADA-aligned USADA framework, Olympic-pathway athletes, and professional athletes in WADA-aligned sports — risks a sanction for any of the five named compounds regardless of medical justification. The 2026 Sports Medicine review documents the wider pattern of unapproved peptide use in sport ^[9].

Three things a reader considering recovery peptides should keep front of mind.

The preclinical-to-clinical gap is real and large. Animal models of tendon repair and wound healing have been historically poor predictors of human clinical outcomes. The preclinical BPC-157 literature is interesting; the inference that "it worked in rats, therefore it works in my patellar tendinopathy" is not supported by the trial data that would establish that.

Source quality is the practical risk. BPC-157 and TB-500 sold through research-chemical suppliers and gray-market channels are not subject to USP standards, third-party potency verification, or sterility testing comparable to compounding-pharmacy operations. Counterfeit and underdosed products are well-documented in the broader unapproved-peptide market. Leaving Category 2 did not put either compound on the list pharmacies may compound from, so a prescription for them still sits outside the ordinary compounding route ^[10].

Athlete exposure is real. A patient subject to anti-doping testing should not use these compounds for any indication, regardless of how the supplying provider frames the regulatory status.

How the two most-used compounds are combined in practice, and what that combination does and does not have behind it, is on our recovery protocol.